The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning

Neuropharmacology

Volumn 57, Issue 2, 2009, Pages 97-108

  Jacob, Wolfgang ^a   Gravius, Andreas ^a   Pietraszek, Malgorzata ^a   Nagel, Jens ^a   Belozertseva, Irina ^b   Shekunova, Elena ^b   Malyshkin, Andrey ^b   Greco, Sergio ^a   Barberi, Caroline ^a   Danysz, Wojciech ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Anxiety; Context freezing; Fenobam; Formalin pain; Learning; Pain

Indexed keywords

DIZOCILPINE; FENOBAM; GABAPENTIN; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; MIDAZOLAM; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG RECEPTOR BINDING; LEARNING DISORDER; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ANALGESICS, NON-NARCOTIC; ANIMALS; ANTI-ANXIETY AGENTS; AVOIDANCE LEARNING; BRAIN; CONDITIONING, CLASSICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEAR; FREEZING REACTION, CATALEPTIC; IMIDAZOLES; LEARNING; LOCOMOTION; MALE; MAZE LEARNING; PAIN; PAIN MEASUREMENT; PHYSICAL STIMULATION; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 67650455900     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.04.011     Document Type: Article

References (65)

1. Anderson J.J., Rao S.P., Rowe B., Giracello D.R., Holtz G., Chapman D.F., Tehrani L., Bradbury M.J., Cosford N.D., and Varney M.A. [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J. Pharmacol. Exp. Ther. 303 (2002) 1044-1051
2. Ballard T.M., Woolley M.L., Prinssen E., Huwyler J., Porter R., and Spooren W. The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology (Berl) 179 (2005) 218-229
3. Bennett G.J., and Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107
4. Berry-Kravis E.M., Hessl D., Coffey S., Hervey C., Schneider A., Yuhas J., Hutchison J., Snape M., Tranfaglia M., Nguyen D.V., and Hagerman R. A pilot open-label single-dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. (2009) (ahead of print online publication)
5. Bhave G., Karim F., Carlton S.M., and Gereau R.W.I. Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat. Neurosci. 4 (2001) 417-423
6. Bikbaev A., Neyman S., Ngomba R.T., Conn J., Nicoletti F., and Manahan-Vaughan D. MGluR5 mediates the interaction between late-LTP, network activity, and learning. PLoS ONE 3 (2008) e2155
7. Brodkin J., Busse C., Sukoff S.J., and Varney M.A. Anxiolytic-like activity of the mGluR5 antagonist MPEP. A comparison with diazepam and buspirone. Pharmacol. Biochem. Behav. 73 (2002) 359-366
8. Christoffersen G.R., Simonyi A., Schachtman T.R., Clausen B., Clement D., Bjerre V.K., Mark L.T., Reinholdt M., Schmith-Rasmussen K., and Zink L.V. MGlu5 antagonism impairs exploration and memory of spatial and non-spatial stimuli in rats. Behav. Brain Res. 191 (2008) 235-245
9. Conn P.J., and Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 205-237
10. Cosford N.D., Roppe J., Tehrani L., Schweiger E.J., Seiders T.J., Chaudary A., Rao S., and Varney M.A. [3H]-Methoxymethyl-MTEP and [3H]-Methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg. Med. Chem. Lett. 13 (2003) 351-354
11. Cosford N.D., Tehrani L., Roppe J., Schweiger E., Smith N.D., Anderson J., Bristow L., Brodkin J., Jiang X., McDonald I., Rao S., Washburn M., and Varney M.A. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 46 (2003) 204-206
12. Dekundy A., Pietraszek M., Schaefer D., Cenci M.A., and Danysz W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res. Bull. 69 (2006) 318-326
13. De Novellis V., Siniscalco D., Galderisi U., Fuccio C., Nolano M., Santoro L., Cascino A., Roth K.A., Rossi F., and Maione S. Blockade of glutamate mGlu5 receptors in a rat model of neuropathic pain prevents early over-expression of pro-apoptotic genes and morphological changes in dorsal horn lamina II. Neuropharmacology 46 (2004) 468-479
14. De Vry J., Kuhl E., Franken-Kunkel P., and Eckel G. Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur. J. Pharmacol. 491 (2004) 137-148
15. Dogrul A., Ossipov M.H., Lai J., Malan Jr. T.P., and Porreca F. Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGLUR(5)) antagonist, in experimental neuropathic pain in rats. Neurosci. Lett. 292 (2000) 115-118
16. Doherty A.J., Palmer M.J., Bortolotto Z.A., Hargreaves A., Kingston A.E., Ornstein P.L., Schoepp D.D., Lodge D., and Collingridge G.L. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. Br. J. Pharmacol. 131 (2000) 239-244
17. Fendt M., and Schmid S. Metabotropic glutamate receptors are involved in amygdaloid plasticity. Eur. J. Neurosci. 15 (2002) 1535-1541
18. Friedmann C.T.H., Davis L.J., Ciccone P.E., and Rubin R.T. Phase II double blind controlled study of a new anxiolytic, fenobam (McN-3377) vs placebo. Curr. Ther. Res. 27 (1980) 144-151
19. Gasparini F., Bruno V., Battaglia G., Lukic S., Leonhardt T., Inderbitzin W., Laurie D., Sommer B., Varney M.A., Hess S.D., Johnson E.C., Kuhn R., Urwyler S., Sauer D., Portet C., Schmutz M., Nicoletti F., and Flor P.J. (R, S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J. Pharmacol. Exp. Ther. 289 (1999) 1678-1687
20. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Velicelebi G., and Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38 (1999) 1493-1503
21. Genkova-Papazova M., Petkova B., Stankova I., Ossowska K., and Lazarova-Bakarova M. Effects of MPEP on avoidance learning in rats. Methods Find. Exp. Clin. Pharmacol. 29 (2007) 205-209
22. Geyer M.A., and Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1071-1079
23. Gravius A., Barberi C., Schäfer D., Schmidt W.J., and Danysz W. The role of group I metabotropic glutamate receptors in acquisition and expression of contextual and auditory fear conditioning in rats - a comparison. Neuropharmacology 51 (2006) 1146-1155
24. Gravius A., Pietraszek M., Schafer D., Schmidt W.J., and Danysz W. Effects of mGluR1 and mGluR5 antagonists on negatively reinforced learning. Behav. Pharmacol. 16 (2005) 113-121
25. Itil T.M., Seaman B.A., Huque M., Mukhopadhyay S., Blasucci D.N.K.T., and Ciccone P.E. The clinical and quantitative EEG effects and plasma levels of fenobam (McN-3377) in subjects with anxiety: an open rising dose tolerance and efficacy study. Curr. Ther. Res. (1978) 708-724
26. Kinney G.G., Burno M., Campbell U.C., Hernandez L.M., Rodriguez D., Bristow L.J., and Conn P.J. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 306 (2003) 116-123
27. Klodzinska A., Tatarczynska E., Chojnacka-Wojcik E., Nowak G., Cosford N.D., and Pilc A. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology 47 (2004) 342-350
28. Lu Y.M., Jia Z.P., Janus C., Henderson J.T., Gerlai R., Wojtowicz J.M., and Roder J.C. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 17 (1997) 5196-5205
29. Mela F., Marti M., Dekundy A., Danysz W., Morari M., and Cenci M.A. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem. 101 (2007) 483-497
30. Nagel J., Belozertseva I., Greco S., Kashkin V., Malyshkin A., Jirgensons A., Shekunova E., Eilbacher B., Bespalov A., and Danysz W. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration. Neuropharmacology 51 (2006) 1163-1171
31. Naie K., and Manahan-Vaughan D. Regulation by metabotropic glutamate receptor 5 of LTP in the dentate gyrus of freely moving rats: relevance for learning and memory formation. Cereb. Cortex 14 (2004) 189-198
32. Neugebauer V. Metabotropic glutamate receptors: novel targets for pain relief. Expert Rev. Neurotherapeutics 1 (2001) 89-106
33. Patel J.B., Martin C., and Malick J.B. Differential antagonism of the anticonflict effects of typical and atypical anxiolytics. Eur. J. Pharmacol. 86 (1982) 295-298
34. Paxinos G., and Watson C. The Rats Brain in Stereotaxic Coordinates (1986), Academic Press, New York
35. Pecknold J.C., McClure D.J., and Appeltauer L. Fenobam in anxious out-patients. Curr. Ther. Res. 27 (1980) 119-123
36. Pecknold J.C., McClure D.J., Appeltauer L., Wrzesinski L., and Allan T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J. Clin. Psychopharmacol. 2 (1982) 129-133
37. Pietraszek M., Gravius A., Schafer D., Weil T., Trifanova D., and Danysz W. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 49 (2005) 73-85
38. Pietraszek M., Sukhanov I., Maciejak P., Szyndler J., Gravius A., Wislowska A., Plaznik A., Bespalov A.Y., and Danysz W. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur. J. Pharmacol. 514 (2005) 25-34
39. Pilc A., Klodzinska A., Branski P., Nowak G., Palucha A., Szewczyk B., Tatarczynska E., Chojnacka-Wojcik E., and Wieronska J.M. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 43 (2002) 181-187
40. Pin J.P., and Acher F. The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr. Drug Target CNS Neurol. Disord. 1 (2002) 297-317
41. Porter R.H., Jaeschke G., Spooren W., Ballard T., Buettelmann B., Kolczewski S., Peters J.U., Prinssen E., Wichmann J., Vieira E., Muehlemann A., Gatti S., Mutel V., and Malherbe P. Fenobam: a clinically validated non-benzodiazepine anxiolytic is a potent, selective and non-competitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. (2005)
42. Rodrigues S.M., Bauer E.P., Farb C.R., Schafe G.E., and LeDoux J.E. The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala. J. Neurosci. 22 (2002) 5219-5229
43. Romano C., Sesma M.A., Mcdonald C.T., Omalley K., Vandenpol A.N., and Olney J.W. Distribution of metabotropic glutamate receptor mglur5 immunoreactivity in rat brain. J. Comp. Neurol. 355 (1995) 455-469
44. Salt T.E., and Eaton S.A. The function of metabotropic excitatory amino acid receptors in synaptic transmission in the thalamus: studies with novel phenylglycine antagonists. Neurochem. Int. 24 (1994) 451-458
45. Schoepp D.D., Jane D.E., and Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38 (1999) 1431-1476
46. Schulz B., Fendt M., Gasparini F., Lingenhohl K., Kuhn R., and Koch M. The metabotropic glutamate receptor antagonist 2-methyl-6- (phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology 41 (2001) 1-7
47. Sevostianova N., and Danysz W. The Modulation of Nociception by Group I Metabotropic Glutamate Receptor Antagonists in Rats (2005), Soc. Neurosci. Abst. 31: 292.15
48. Sevostianova N., and Danysz W. Analgesic effects of mGlu1 and mGlu5 receptor antagonists in the rat formalin test. Neuropharmacology 51 (2006) 623-630
49. Shigemoto R., Nomura S., Ohishi H., Sugihara H., Nakanishi S., and Mizuno N. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 163 (1993) 53-57
50. Simonyi A., Schachtman T.R., and Christoffersen G.R. The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect. 18 (2005) 353-361
51. Spooren W.P., Gasparini F., Bergmann R., and Kuhn R. Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6- (phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur. J. Pharmacol. 406 (2000) 403-410
52. Spooren W.P., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., Porsolt R.D., and Gentsch C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 295 (2000) 1267-1275
53. Spooren W.P., Schoeffter P., Gasparini F., Kuhn R., and Gentsch C. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur. J. Pharmacol. 435 (2002) 161-170
54. Spooren W., Ballard T., Gasparini F., Amalric M., Mutel V., and Schreiber R. Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav. Pharmacol. 14 (2003) 257-277
55. Steckler T., Oliveira A.F., Van Dyck C., Van Craenendonck H., Mateus A.M., Langlois X., Lesage A.S., and Prickaerts J. Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task. Behav. Brain Res. 164 (2005) 52-60
56. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., Kuhn R., and Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 132 (2001) 1423-1430
57. Testa C.M., Standaert D.G., Young A.B., and Penney Jr. J.B. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J. Neurosci. 14 (1994) 3005-3018
58. Vivancos G.G., Verri Jr. W.A., Cunha T.M., Schivo I.R., Parada C.A., Cunha F.Q., and Ferreira S.H. An electronic pressure-meter nociception paw test for rats. Braz. J. Med. Biol. Res. 37 (2004) 391-399
59. Walker K., Bowes M., Panesar M., Davis A., Gentry C., Kesingland A., Gasparini F., Spooren W., Stoehr N., Pagano A., Flor P.J., Vranesic I., Lingenhoehl K., Johnson E.C., Varney M., Urban L., and Kuhn R. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology 40 (2001) 1-9
60. Walker K., Reeve A., Bowes M., Winter J., Wotherspoon G., Davis A., Schmid P., Gasparini F., Kuhn R., and Urban L. mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology 40 (2001) 10-19
61. Wenk G.L. Assessment of spatial memory using the radial arm maze and Morris water maze. Curr. Protoc. Neurosci. (1997) Chapter 8, Unit 8.5A
62. Wroblewski J.T., and Danysz W. Modulation of glutamate receptors: molecular mechanisms and functional implications. Annu. Rev. Pharmacol. Toxicol. 29 (1989) 441-474
63. Wu W.N., McKown L.A., and O'Neill P.J. In vitro and in vivo metabolism of the antianxiolytic agent fenobam in the rat. J. Pharm. Sci. 84 (1995) 185-189
64. Wu W.N., and McKown L.A. Recent advances in biotransformation of CNS and cardiovascular agents. Curr. Drug Metab. 1 (2000) 255-270
65. Zhu C.Z., Wilson S.G., Mikusa J.P., Wismer C.T., Gauvin D.M., Lynch III J.J., Wade C.L., Decker M.W., and Honore P. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur. J. Pharmacol. 506 (2004) 107-118